Tomorrow's BioPharma landscape viewed by EvaluatePharma

The quantity of biologic drugs on the market will likely soar by 2018, according to analysts at Evaluate Pharma, who says a thorough analysis of companies listed on the Nasdaq Biotechnology Index (NBI) revealed that, while less than 10% of these companies’ currently marketed products are biologic drugs - pharmaceuticals derived from living organisms - these products comprise a hefty 40% of the companies’ drug pipelines.

The EvaluatePharma report also reveals the diversity of the 117 companies listed on the index, with insights about pipeline development and consensus sales estimates. The analysis points to a growing focus on biologics, including drugs treating cancer, infection and central nervous system diseases. The report is available for download at www.evaluatepharma.com/NBI2012.

The Nasdaq Biotech Index is cited all around the world, but rarely do we see a detailed aggregate analysis of these leading, publicly traded biotechnology companies. This analysis provides insight into the breadth and scope of today’s products and looks at where this dynamic sector is heading, says EvaluatePharma.